Net sales were 129,540 million yen (Year-over-Year (YoY) increase of 6.5%), operating income was 5,404 million yen (\u22124.1%), ordinary income was 5,630 million yen (\u22124.7%), and net income attributable to owners of parent for the quarter was 3,788 million yen (\u22125.2%). Full-year forecasts for the fiscal year ending May 2027 are maintained. Dividend forecast assumes 48 yen at the end of Q2 and 48 yen at the end of Q3, totaling 96 yen. Segment information is omitted because operations are mainly in the drugstore business. Opened 5 new stores and closed 1 store; there were openings and closures of attached dispensing pharmacies. Consolidated financial position: total assets 249,872 million yen, net assets 154,988 million yen, and equity ratio 62.0%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3148","jir_company_name":"Create SD Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/3148-20261005-01.pdf","jir_short_summary":"Net sales were 129,540 million yen (Year-over-Year (YoY) increase of 6.5%), operating income was 5,404 million yen (\u22124.1%), ordinary income was 5,630 million yen (\u22124.7%), and net income attributable to owners of parent for the quarter was 3,788 million yen (\u22125.2%). Full-year forecasts for the fiscal year ending May 2027 are maintained. Dividend forecast assumes 48 yen at the end of Q2 and 48 yen at the end of Q3, totaling 96 yen. Segment information is omitted because operations are mainly in the drugstore business. Opened 5 new stores and closed 1 store; there were openings and closures of attached dispensing pharmacies. Consolidated financial position: total assets 249,872 million yen, net assets 154,988 million yen, and equity ratio 62.0%.","jir_summary":"### Performance Summary\nConsolidated net sales for Q1 were 129,540 million yen, securing a 6.5% YoY increase. However, operating income was 5,404 million yen (\u22124.1%), ordinary income was 5,630 million yen (\u22124.7%), and net income attributable to owners of parent for the quarter was 3,788 million yen (\u22125.2%), falling below the prior year on the profit side. A factor in the decrease in quarterly net income was an increase in selling, general and administrative expenses (for example: higher salaries, allowances, increased provision for bonuses, and higher goodwill amortization). Full-year forecast remains unchanged from the initial outlook. The company continues to expand its store network centered on drugstores and to grow attached dispensing pharmacies.\n\n### Outlook and Capital Structure\nFor the fiscal year ending May 2027, the full-year forecasts are currently maintained at previously announced levels. Net sales are expected to be 541,000 million yen, operating income 25,300 million yen, ordinary income 26,500 million yen, and net income attributable to owners of parent 17,000 million yen. The dividend policy anticipates 48 yen at the end of Q2 and 48 yen at the end of Q3, totaling 96 yen for the year. Financial position: total assets 249,872 million yen, net assets 154,988 million yen, treasury stock at Q1 of fiscal 2027 is \u22122,705 million yen, and the equity ratio is 62.0%, indicating stability. The company will continue to strengthen store development and dispensing pharmacy cooperation while implementing measures to address intensifying competition.","jir_financial_highlights":"Net Sales: 129,540 (YoY increase of 6.5%)\nOperating Income: 5,404 (YoY \u22124.1%)\nOrdinary Income: 5,630 (YoY \u22124.7%)\nNet Income Attributable to Owners of Parent (Quarter): 3,788 (YoY \u22125.2%)\nTotal Assets: 249,872 (Decrease from the end of the previous fiscal year)\nNet Assets: 154,988 (Increase from the end of the previous fiscal year)\nEquity Ratio: 62.0% (Increase from the previous fiscal year)","jir_category":"","jir_hashtags":"#CreateSDHoldings, #FinancialResults, #Drugstore, #MidtermPlanNextSTAGE2030","jir_key_figures":"Net Sales: 129,540 million yen (YoY increase of 6.5%)\nOperating Income: 5,404 million yen (YoY \u22124.1%)\nNet Income Attributable to Owners of Parent (Quarter): 3,788 million yen (YoY \u22125.2%)","jir_meta_title":"Create SD Holdings Co., Ltd. Q1 Financial Summary for FY Ending May 2027 | Net Sales 129,540 million yen (YoY +6.5%)","jir_meta_description":"Q1 financial summary for Create SD Holdings Co., Ltd. Net sales 129,540 million yen, operating income 5,404 million yen, net income 3,788 million yen. Full-year forecasts maintained; dividend forecast totals 96 yen. Company continues drugstore-centered store strategy.","jir_og_title":"Create SD Holdings Co., Ltd. | Q1 Financial Summary for FY Ending May 2027","jir_og_description":"Net sales 129,540 million yen, operating income 5,404 million yen, net income 3,788 million yen. Full-year forecasts are maintained. Company will continue to expand stores and strengthen dispensing pharmacy cooperation.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026Q1\\\",\\\"2026Q2\\\",\\\"2026Q3\\\",\\\"2026Q4\\\",\\\"2027Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[129540,0,0,0,0],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026Q1\\\",\\\"2026Q2\\\",\\\"2026Q3\\\",\\\"2026Q4\\\",\\\"2027Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[5604,0,0,0,5404],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}]","ir_related_company":8890,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-127433","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n